The stock of Spark Therapeutics Inc (NASDAQ:ONCE) is a huge mover today! About 539,898 shares traded hands or 33.86% up from the average. Spark Therapeutics Inc (NASDAQ:ONCE) has risen 27.27% since April 4, 2016 and is uptrending. It has outperformed by 26.18% the S&P500.
The move comes after 7 months positive chart setup for the $1.34 billion company. It was reported on Nov, 4 by Barchart.com. We have $56.95 PT which if reached, will make NASDAQ:ONCE worth $402.00 million more.
Spark Therapeutics Inc (NASDAQ:ONCE) Ratings Coverage
Out of 10 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 50% are positive. Spark Therapeutics has been the topic of 12 analyst reports since August 21, 2015 according to StockzIntelligence Inc. The stock of Spark Therapeutics Inc (NASDAQ:ONCE) earned “Neutral” rating by Chardan Capital Markets on Wednesday, December 23. The rating was downgraded by Zacks on Wednesday, September 2 to “Sell”. Evercore initiated Spark Therapeutics Inc (NASDAQ:ONCE) rating on Tuesday, April 12. Evercore has “Buy” rating and $37 price target. The firm earned “Hold” rating on Friday, August 21 by Zacks. The rating was downgraded by Wunderlich to “Hold” on Thursday, December 24. The stock of Spark Therapeutics Inc (NASDAQ:ONCE) earned “Hold” rating by Jefferies on Thursday, June 2. The rating was initiated by Goldman Sachs with “Neutral” on Wednesday, March 30. The stock of Spark Therapeutics Inc (NASDAQ:ONCE) has “Buy” rating given on Friday, June 3 by Cantor Fitzgerald. As per Monday, October 5, the company rating was maintained by Roth Capital. As per Thursday, June 23, the company rating was maintained by Cantor Fitzgerald.
According to Zacks Investment Research, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 2.11 in 2016 Q2. Its down 0.03, from 2.14 in 2016Q1. The ratio turned negative, as 18 funds sold all Spark Therapeutics Inc shares owned while 18 reduced positions. 28 funds bought stakes while 48 increased positions. They now own 23.88 million shares or 24.93% more from 19.12 million shares in 2016Q1.
Baker Bros Limited Partnership, a New York-based fund reported 1.32M shares. The Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in Spark Therapeutics Inc (NASDAQ:ONCE). American Intll Gru last reported 0% of its portfolio in the stock. Emerald Mutual Fund Advisers Trust has invested 0.14% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE). Legal And General Gru Public Ltd Co holds 2,714 shares or 0% of its portfolio. Metropolitan Life Company Ny accumulated 12,778 shares or 0% of the stock. Brookside Capital Mngmt Lc holds 0.91% or 424,114 shares in its portfolio. Moreover, Aqr Limited Co has 0% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 30,015 shares. The Colorado-based Alps has invested 0.02% in Spark Therapeutics Inc (NASDAQ:ONCE). Ubs Oconnor Limited Com has 18,920 shares for 0% of their US portfolio. Iguana Healthcare Limited Liability Co last reported 1.25% of its portfolio in the stock. Blackrock Japan, a Japan-based fund reported 26 shares. Glenmede Com Na holds 5,000 shares or 0% of its portfolio. State Board Of Administration Of Florida Retirement Systems last reported 0% of its portfolio in the stock. California State Teachers Retirement Sys has invested 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE).
More notable recent Spark Therapeutics Inc (NASDAQ:ONCE) news were published by: Fool.com which released: “Spark Therapeutics Inc. Tumbled as Much as 25% on Thursday — Here’s Why” on November 03, 2016, also Nasdaq.com with their article: “Spark Therapeutics (ONCE) Shares Cross Below 200 DMA” published on November 03, 2016, Reuters.com published: “BRIEF-Spark Therapeutics Q3 loss per share $1.07” on November 03, 2016. More interesting news about Spark Therapeutics Inc (NASDAQ:ONCE) were released by: Philly.com and their article: “Spark Therapeutics releases gene-therapy data” published on August 10, 2016 as well as Fool.com‘s news article titled: “Why Spark Therapeutics Caught Fire and Rallied Higher Today” with publication date: May 19, 2016.
ONCE Company Profile
Spark Therapeutics, Inc. (Spark), incorporated on March 13, 2013, is engaged in developing products in the field of gene therapy. The Firm focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. The Company’s SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). The Company’s product candidates include SPK-CHM and SPK-FIX. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. The Firm is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.